Idecabtagene vicleucel (ide-cel) versus standard regimens in patients (pts) with triple-class-exposed (TCE) relapsed and refractory multiple myeloma (RRMM): A KarMMa-3 analysis in the modified intent-to-treat (mITT) population Meeting Abstract
| Authors: | Scheid, C.; Manier, S.; Ailawadhi, S.; Rodríguez-Otero, P.; Arnulf, B.; Patel, K.; Solomon, S. R.; Baz, R.; Jagannath, S.; Raje, N.; Mateos, M. V.; Abdallah, A. O.; Einsele, H.; Giralt, S.; Pabst, T.; Perrot, A.; Lin, Y.; Truppel-Hartmann, A.; Bhatnagar, R.; Felten, J.; Caia, A.; Piasecki, J.; Cook, M.; Moreau, P. |
| Abstract Title: | Idecabtagene vicleucel (ide-cel) versus standard regimens in patients (pts) with triple-class-exposed (TCE) relapsed and refractory multiple myeloma (RRMM): A KarMMa-3 analysis in the modified intent-to-treat (mITT) population |
| Meeting Title: | 36. Deutscher Krebskongress - Fortschritt gemeinsam gestalten |
| Journal Title: | Oncology Research and Treatment |
| Volume: | 47 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2024 Feb 21-24 |
| Meeting Location: | Berlin, Germany |
| ISSN: | 2296-5270 |
| Publisher: | S. Karger AG |
| Date Published: | 2024-02-01 |
| Start Page: | 142 |
| Language: | English |
| ACCESSION: | WOS:001332646400335 |
| PROVIDER: | wos |
| DOI: | 10.1159/000535363 |
| Notes: | Meeting Abstract: 237 -- 'The 36th German Cancer Congress - Building Progress Together' -- Located in the section 'Novel Therapeutics: Targeted Therapies, Immunotherapies, Cellular Therapies' -- Source: Wos |
